ACME Solar Holdings (ACME Solar), through its various subsidiaries, has secured debt tie-up of INR 4,725 crore from leading Indian financial institutions to fund the construction of renewable energy projects and optimize its capital structure by reducing financing costs. The capital raise includes financing and refinancing for a tenor ranging from 18 to 20 years for the projects mentioned below:

New Greenfield Financings: Rs 2,716 crore from Power Finance Corporation (PFC) for 300 MW ACME Sigma FDRE project (Renewable with four hours of battery storage) and First greenfield Project financing for Acme from National Bank for Financing Infrastructure Development (NaBFID) of Rs 800 crore from for 150 MW ACME Platinum Solar + ESS project (with two hours of battery storage with 50% availability). Both these projects have connectivity in place and are in advance stages of construction.

Refinancing: Rs 1,209 crore secured from Yes Bank towards refinancing operational project of 300 MW ACME Sikar Solar project enabling reduction in cost of debt initially by 170 bps and eventually by 195 bps. This is first long-term refinancing from Yes Bank for ACME Solar.

With this round of financing, in the current financial year company has secured ~Rs 10,590 crore of greenfield financing leading to overall debt tie up of more than 90% of PPA signed under construction projects. Further, company has refinanced debt of ~Rs 3,380 crore, achieving a ~135 bps rate reduction on refinanced debt and additional rate reduction of ~ 60 bps on ~ Rs 4,035 crore debt for other projects which includes two operational projects moving to fixed rate regime with existing lender. This initiative is consistent with the Company's long-term funding strategy to maintain a well-diversified and strategic mix of fixed and floating rate borrowings.

Non-fund based limits- ACME Solar has also expanded Non-fund based limits from various Banks this year including ICICI Bank, Standard Chartered Bank, First Abu Dhabi Bank, EXIM Bank etc. These limits assist in reducing cost of debt through trade finance during construction stage of project.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Travatan Z Ophthalmic Solution, 0.004%, of Sandoz Inc. (Sandoz). Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Travoprost Ophthalmic Solution USP, 0.004%, has an estimated market size of US$ 61 million for twelve months ending September 2025 according to IQVIA.

Alembic has a cumulative total of 232 ANDA approvals (212 final approvals and 20 tentative approvals) from USFDA.

Artefact Projects has received a contract from National Highways Authority of India to provide consultancy services for independent Engineer Services during operation and Maintenance of (1) Four Laning of sethiyathope to Cholapuram Section from Km 65+960 to Km 1 16+440 of NH -36 (old No. NH-45c) and (ii) Four Laning of Cholapuram to Thanjavur section from Km 116+440 to Km 164+275 of NH-36 ( old No. NH-45C) in the State of Tamil Nadu in association with pioneer Infra Consultants and Neoteric Consultant LLP. The contract valued at Rs 7.67 crore is valid for 60 months.

Arvind Fashions has allotted 7,500 equity shares under ESOS on 18 December 2025.

Ashika Credit Capital announced the incorporation of a wholly owned subsidiary, Ashika Global Custodial Services on 17 December 2025 to carry out custodial services, subject to receipt of necessary approvals from the concerned regulatory authorities.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from 08 December to 17 December 2025.

At the end of the current inspection, a ‘Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines.

Axis Bank has appointed Malavika R. Harita (DIN: 09005600) as an additional independent director of the Bank for a period of four years with effect from 18 December 2025 up to 17 December 2029 (both days inclusive), subject to approval of shareholders.

Balkrishna Paper Mills will hold a meeting of the Board of Directors of the Company on 23 December 2025.

Banganga Paper Industries announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 14 January 2026.

Birlasoft has allotted 1,47,241 equity shares under Birlasoft Share Incentive Plan on 18 December 2025. With this allotment, the paid-up capital of the Company has increased to Rs. 55,73,80,370/- divided into 27,86,90,185 equity shares of face value of Rs. 2/- each.